Company intelligence / Profile preview

Nippon Kayaku Co., Ltd.

Chiyoda-ku, Tokyo, Japannipponkayaku.co.jp ↗

Ownership: Public · 4272
Employees: ~5174
Development stage: NDA

Overview

Nippon Kayaku has developed various pharmaceutical products including anti-cancer drugs, with Bleomycin being their first anti-cancer drug developed in 1969. They also developed MILLISROL, the world's first water-soluble nitroglycerin injections in 1984[4].

Therapeutic areas: OncologyCardiovascular
Modalities: Small moleculesAnti-cancer drugs
Industry: Biotech

Drug pipeline

11 assets

benzalkonium chloride

10 more assets in the full pipeline.

Request access →

Partnerships

Joint venture with Geigy (Swiss company)[1]

Beyond the preview

Go deeper on Nippon Kayaku Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nippon Kayaku Co., Ltd..

Explore the full profile